• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay.

作者信息

Hasegawa Yoshinori, Sarashina Takeshi, Ando Maki, Kitagawa Chiyoe, Mori Atsuo, Yoneyama Masao, Ando Yuichi, Shimokata Kaoru

出版信息

Clin Chem. 2004 Aug;50(8):1479-80. doi: 10.1373/clinchem.2004.034694.

DOI:10.1373/clinchem.2004.034694
PMID:15277366
Abstract
摘要

相似文献

1
Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay.通过新开发的侵入法快速检测UGT1A1基因多态性。
Clin Chem. 2004 Aug;50(8):1479-80. doi: 10.1373/clinchem.2004.034694.
2
Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.使用Invader UGT1A1分子检测法筛查伊立替康治疗的不良反应。
Expert Rev Mol Diagn. 2006 Jul;6(4):527-33. doi: 10.1586/14737159.6.4.527.
3
Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray.通过新型DNA微阵列快速灵敏检测与伊立替康毒性相关的UGT1A1基因多态性
Cancer Sci. 2017 Jul;108(7):1504-1509. doi: 10.1111/cas.13272. Epub 2017 Jun 5.
4
Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar).用于检测伊立替康毒性的Invader UGT1A1分子检测法。一种针对癌症化疗药物伊立替康（开普拓）毒性风险增加的基因检测。
Med Lett Drugs Ther. 2006 May 8;48(1234):39-40.
5
UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.UGT1A1基因多态性可预测伊立替康毒性：不断演变的证据。
AAPS PharmSci. 2001;3(3):3. doi: 10.1208/ps0303_commentary2.
6
Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.伊立替康为基础的化疗后患儿出现持续性中性粒细胞减少症，与 UGT1A1 和 SLCO1B1 多态性相关。
Arch Dis Child. 2009 Dec;94(12):981-2. doi: 10.1136/adc.2009.163089. Epub 2009 Jul 15.
7
Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).UGT1A1*28 或 *6 多态性的经治肺癌患者中伊立替康的 I 期研究：九州肺癌研究组（LOGIK1004A）的结果。
Thorac Cancer. 2017 Jan;8(1):40-45. doi: 10.1111/1759-7714.12407. Epub 2016 Nov 24.
8
UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.UGT1A1*28及其他UGT1A基因多态性作为伊立替康毒性的决定因素
J Chemother. 2008 Apr;20(2):158-65. doi: 10.1179/joc.2008.20.2.158.
9
Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.对接受伊立替康化疗的日本患者进行UGT1A1*28和*6基因检测。
Ann Oncol. 2008 Dec;19(12):2089-90. doi: 10.1093/annonc/mdn645. Epub 2008 Oct 26.
10
Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.UGT1A1*6、UGT1A1*28和ABCB1-3435C>T基因多态性对中国癌症患者伊立替康所致毒性的影响。
Int J Clin Pharmacol Ther. 2016 Mar;54(3):193-9. doi: 10.5414/CP202442.

引用本文的文献

1
Rapid detection of the irinotecan-related UGT1A1*28 polymorphism by asymmetric PCR melting curve analysis using one fluorescent probe.采用单荧光探针不对称 PCR 熔解曲线分析法快速检测伊立替康相关的 UGT1A1*28 多态性。
J Clin Lab Anal. 2022 Aug;36(8):e24578. doi: 10.1002/jcla.24578. Epub 2022 Jun 29.
2
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.在无严重肾功能衰竭的癌症患者中，肝脏摄取转运体OATP1B1对SN-38药代动力学个体间差异的贡献极小。
Cancer Chemother Pharmacol. 2021 Sep;88(3):543-553. doi: 10.1007/s00280-021-04314-1. Epub 2021 Jun 11.
3
Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.
UGT1A1 多态性对日本小细胞肺癌患者依托泊苷联合铂类化疗引起中性粒细胞减少的影响。
Int J Clin Oncol. 2019 Mar;24(3):256-261. doi: 10.1007/s10147-018-1358-4. Epub 2018 Oct 17.
4
Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray.通过新型DNA微阵列快速灵敏检测与伊立替康毒性相关的UGT1A1基因多态性
Cancer Sci. 2017 Jul;108(7):1504-1509. doi: 10.1111/cas.13272. Epub 2017 Jun 5.
5
Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia.日本慢性髓性白血病患者中尼洛替尼严重毒性与UGT1A1基因多态性的关联
Int J Clin Oncol. 2014 Apr;19(2):391-6. doi: 10.1007/s10147-013-0562-5. Epub 2013 Apr 23.
6
Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.伊立替康的药物遗传学：基于种族的伊立替康不良反应预测。
World J Gastrointest Surg. 2010 Jan 27;2(1):14-21. doi: 10.4240/wjgs.v2.i1.14.
7
Patient profiling for treatment toxicity: potential use of clinical and genomic factors.患者治疗毒性特征分析：临床和基因组因素的潜在应用。
Curr Oncol Rep. 2011 Feb;13(1):37-41. doi: 10.1007/s11912-010-0141-0.
8
High-throughput single-base mismatch detection for genotyping of UDP-glucuronosyltransferase (UGT1A1) with probe capture assay coupled with modified allele-specific primer extension reaction (MASPER).采用探针捕获与改良等位基因特异性引物延伸反应（MASPER）相结合的高通量单碱基错配检测法对 UDP-葡糖醛酸基转移酶 1A1（UGT1A1）进行基因分型。
J Clin Lab Anal. 2010;24(2):85-91. doi: 10.1002/jcla.20359.
9
Pharmacogenetics and pharmacogenomics of anticancer agents.抗癌药物的药物遗传学和药物基因组学
CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. doi: 10.3322/caac.20002.
10
Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.UGT1A1基因分型能否降低接受伊立替康治疗的转移性结直肠癌患者的发病率和死亡率？一项基于证据的综述。
Genet Med. 2009 Jan;11(1):21-34. doi: 10.1097/GIM.0b013e31818efd77.